Eltrombopag-d3

Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].

1133710-20-9

SB-497115-d3

12352005

Apoptosis; Bacterial; Isotope-Labeled Compounds; Thrombopoietin Receptor

Anti-infection; Apoptosis; Immunology/Inflammation; Others

COVID-19-immunoregulation

Cancer; Infection; Cardiovascular Disease

O=C(O)C1=CC(C2=C([2H])C([2H])=C([2H])C(N/N=C3C(C)=NN(C/3=O)C4=CC=C(C(C)=C4)C)=C2O)=CC=C1

C25H19D3N4O4

445.49

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27 (2) :424-30.|[3]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33 (1) :85-93.|[4]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel) . 2021 Nov 9;10 (11) :1372.|[5]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[6]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47 (5) :1696-702.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W713365/

Isotope-Labeled Compounds

No Development Reported